863329-64-0

Usage

Uses

Used in Chemical and Biological Research:
Cytidine, N-benzoyl-2'-C-methyl-, 3',5'-dibenzoate (9CI) is utilized as a research compound for the study of nucleic acid modifications. Its unique structure allows for the exploration of how the protection of certain functional groups by benzoyl groups can influence the properties and reactivity of nucleic acids.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Cytidine, N-benzoyl-2'-C-methyl-, 3',5'-dibenzoate (9CI) is used as a precursor in the development of nucleoside analogs. These analogs can be further modified to create new drugs that target specific pathways in nucleic acid metabolism, potentially leading to treatments for various diseases and conditions.
Used in Drug Development:
Cytidine, N-benzoyl-2'-C-methyl-, 3',5'-dibenzoate (9CI) is employed as a key intermediate in the synthesis of novel therapeutic agents. Its unique chemical properties make it a valuable component in the design of drugs that can modulate nucleic acid function, offering new avenues for the treatment of diseases associated with abnormal nucleic acid activity.

Upstream product

• 863329-62-8 N⁴-benzoyl-1-(2-C-methyl-3,5-di-O-benzoyl-β-D-arabinofuranosyl)cytosine 
• 817204-35-6 N⁴-benzoyl-2'-C-methyl-β-D-arabinofuranosylcytosine 
• 98-88-4 benzoyl chloride 
• 817204-34-5 N⁴-benzoyl-1-[2-C-methyl-3,5-O-(tetraisopropyldisiloxane-1,3-diyl)-β-D-arabinofuranosyl]cytosine 
• 93-97-0 benzoic acid anhydride 
• 13089-48-0 N₄-benzoylcytidine 
• 69304-43-4 1-[3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-β-D-ribofuranosyl]-N⁴-benzoylcytosine 
• 119411-03-9 N-[2-Oxo-1-((2R,3aR,9aR)-5,5,7,7-tetraisopropyl-3-oxo-tetrahydro-1,4,6,8-tetraoxa-5,7-disila-cyclopentacycloocten-2-yl)-1,2-dihydro-pyrimidin-4-yl]-benzamide 
• 65-46-3 CYTIDINE 

Downstream Products

• 874638-98-9 N-(1-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide 

Relevant academic research and scientific papers

High-yield synthesis method of sofosbuvir and sofosbuvir prepared with method

The invention relates to a high-yield synthesis method of sofosbuvir and sofosbuvir prepared with the method. The method comprises steps as follows: (a) cytidine and benzoic anhydride are dissolved in a first organic solvent for a reaction; TIDPSCl2 is ad

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

Design, synthesis, and antiviral activity of 2′-deoxy-2′- fluoro-2′-C-methylcytidine, a potent inhibitor of hepatitis C virus replication

The pyrimidine nucleoside beta-D-2′-deoxy-2′-fluoro-2′-C- methylcytidine (1) was designed as a hepatitis C virus RNA-dependent RNA polymerase (HCV RdRp) inhibitor. The title compound was obtained by a DAST fluorination of N4-benzoyl-1-(2-methyl-3,5-di-O-benzoyl-β-D- arabinofuranosyl]cytosine (6) to provide N4-benzoyl-1-[2-fluoro-2- methyl-3,5-di-O-benzoyl-β-D-ribofuranosyl]cytosine (7a). The protected 2′-C-methylcytidine (7c) was obtained as a byproduct from the DAST fluorination and allowed for the preparation of two biologically active compounds from a common precursor. Compound 1 and 2′-C-methylcytidine were assayed in a subgenomic HCV replicon assay system and found to be potent and selective inhibitors of HCV replication. Compound 1 shows increased inhibitory activity in the HCV replicon assay compared to 2′-C-methylcytidine and low cellular toxicity.